San Francisco · ketamine decision tool

Before you pay the package price.

A calm room, a medical title, and the word transformative tell you almost nothing. Name the drug. Find the licence. Inspect the monitoring. Price the whole course.

Evidence and regulatory facts checked August 29, 2026. Licensed-prescriber review is pending; no clinical-review badge is claimed.

First distinction

Which thing is the clinic actually selling?

FDA-approved use

Spravato (esketamine)

A nasal spray with specific adult depression indications. It must be administered in a certified health-care setting under direct observation, followed by at least two hours of monitoring.¹

Off-label use

Ketamine

FDA-approved as an anesthetic, not for a psychiatric condition. IV, IM, or other psychiatric use is off-label. Evidence, dose, monitoring, and maintenance standards must be explained rather than borrowed from the Spravato label.² ³

Not FDA-approved

Compounded ketamine

FDA has not reviewed a compounded oral or nasal product for safety, effectiveness, or quality. FDA has specifically warned about psychiatric use without onsite monitoring.²

What the evidence permits

Not a first-treatment shortcut.

The 2022 VA/DoD depression guideline suggests against ketamine or esketamine as an initial medication choice. After a partial or absent response to an adequate medication trial, it lists switching to ketamine or esketamine among several options, not ranked above psychotherapy or other medication strategies.³

Compare ketamine and esketamine →
Private on this page

Five checks before a deposit.

Nothing you mark or write is sent or saved. Print a blank copy, or use the boxes while the page is open.

0 of 15 answers in hand
01 · Name the treatment

One word is hiding three different products.

Write down the generic drug and route. Do not let “ketamine therapy” stand in for the answer.

02 · Test the reason

Ask why this treatment, now.

A sale is not a treatment rationale. The answer should start with your diagnosis, prior care, medical history, and the alternatives still available.

03 · Find the accountable person

A certificate is not a California licence.

Record the prescriber—not only the brand name of the clinic. Verify the person independently before paying a package deposit.

04 · Inspect the room

Monitoring is part of the treatment.

Spravato has a required supervised program. Off-label ketamine does not inherit that protocol merely because the drugs are related.

05 · Price the whole course

A session price is not a course price.

Ask for screening, drug sessions, monitoring, preparation, follow-up, maintenance, cancellation, and insurance assumptions in one written answer.

Pause the purchase

Six answers that should stop the deposit.

  • “Ketamine is FDA-approved for depression.”
  • “Spravato can be taken home.”
  • “Our certification is all the licence information you need.”
  • “We use the same monitoring for everyone.”
  • “Buy the package first; the prescriber will decide later.”
  • “Integration is required, but we cannot separate its price.”

A pause is not a verdict that a clinic is unsafe. It is a reason to get a specific answer before money makes the decision harder to revisit.

San Francisco alternatives

The marketed treatment is not the only next move.

If your plan has no appointment

Ask the plan to locate care within California’s timely-access standard and record the call. A clinic’s cash package is not your insurer’s escape hatch.

Use the 10-day request script →

If you use San Francisco’s public system

The city’s 2026 member handbook lists the 24/7 Behavioral Health Access Line at 1-888-246-3333 (TTY 711). Ask for screening and the treatment routes you qualify for; do not assume ketamine is one of them.⁶

If the offer is a research study

Verify the San Francisco location, recruitment status, sponsor, costs, compensation, and official contact in the federal record. A clinic waitlist is not a registered trial.

Search ClinicalTrials.gov →
Verify outside the clinic site

Two records the advertisement cannot edit.

Sources

The documents behind the checklist.

  1. U.S. Food and Drug Administration, Spravato prescribing information, revised 2025: indications, boxed warnings, REMS, observation, blood-pressure assessment, and driving restriction.
  2. U.S. Food and Drug Administration, compounding risk alerts: compounded ketamine products for psychiatric disorders and risks without onsite monitoring.
  3. Department of Veterans Affairs and Department of Defense, 2022 Clinical Practice Guideline for Major Depressive Disorder: initial treatment and options after partial or no response.
  4. Medical Board of California, physician licence verification.
  5. California State Board of Pharmacy, pharmacy and compounding licence verification.
  6. California Department of Health Care Services and San Francisco Behavioral Health Services, 2026 member handbook: Behavioral Health Access Line and county access responsibilities.
  7. Centers for Medicare & Medicaid Services, good faith estimates for uninsured or self-pay care.

Educational information, not individual medical advice or a determination that a clinic is safe. Evidence and regulatory facts checked August 29, 2026. Licensed-prescriber review is pending.